Search

Displaying results 3931 - 3940 of 10000 in total
  1. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    Revakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). … [A265125,L46762] It is an allogeneic encapsulated cell-based gene therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotropic factor

    Categories: Complex Mixtures
  2. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. … PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.

  3. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    [A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as [DB00047] and [DB01307], which have a duration of action of 20-24 hours, insulin degludec provides a consistent level … Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.

    Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETProducts: TRESIBA® 100 U/ML, Tresiba® FlexTouch® 100 U/ml Solution for Injection
  4. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi trial, where a confirmed objective response rate was observed to be 41% compared

  5. Drug

    Utatrectinib

    go.drugbank.com/drugs/DB21295
    Investigational

    Utatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Utatrectinib is a tropomyosin receptor kinase (TRK) inhibitor. … Utatrectinib is under investigation in clinical trial NCT01468324 (AZD7451 for Recurrent Gliomas). Utatrectinib has a monoisotopic molecular weight of 382.17 Da.

  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH … One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO

  7. Drug

    Tedizolid phosphate

    go.drugbank.com/drugs/DB09042
    Approved

    This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].

  8. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.

  9. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns … [A38834] It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations.

  10. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness.